Tharimmune announces positive topline data with th104, its lead candidate for moderate-to-severe pruritus in chronic liver disease patients

Phase 1 ex-us trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose th104 was well tolerated with no unexpected treatment-emergent adverse events comparable to previous phase 1 studies company funded into early 2025 and expects bridging pk data in the us and phase 2a results for chronic pruritus in primary biliary cholangitis (pbc) in 2024 bridgewater, nj / accesswire / december 11, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announces positive phase 1 data with th104, a proprietary transmucosal buccal film which easily adheres to the inside of the mouth. the phase 1 trial was a single-dose, single-center, open-label, randomized, study of th104 transmucosal buccal film conducted in india in two different cohorts.
THAR Ratings Summary
THAR Quant Ranking